Pular para o conteúdo
Merck
  • Mesenchymal Stromal Cells Inhibit Inflammatory Lymphangiogenesis in the Cornea by Suppressing Macrophage in a TSG-6-Dependent Manner.

Mesenchymal Stromal Cells Inhibit Inflammatory Lymphangiogenesis in the Cornea by Suppressing Macrophage in a TSG-6-Dependent Manner.

Molecular therapy : the journal of the American Society of Gene Therapy (2018-01-05)
Hyun Beom Song, Se Yeon Park, Jung Hwa Ko, Jong Woo Park, Chang Ho Yoon, Dong Hyun Kim, Jeong Hun Kim, Mee Kum Kim, Ryang Hwa Lee, Darwin J Prockop, Joo Youn Oh
RESUMO

The cornea is a transparent tissue devoid of blood and lymphatic vessels. However, various inflammatory conditions can cause hemangiogenesis and lymphangiogenesis in the cornea, compromising transparency and visual acuity. Mesenchymal stem/stromal cells (MSCs) have therapeutic potentials in a variety of diseases because of anti-inflammatory properties. Herein, we investigated the effects of MSCs on corneal angiogenesis using a model of suture-induced inflammatory corneal neovascularization. Data demonstrated that an intravenous administration of MSCs suppressed corneal inflammation and neovascularization, inhibiting both hemangiogenesis and lymphangiogenesis. MSCs reduced the levels of vascular endothelial growth factor (VEGF)-C, VEGF-D, Tek, MRC1, and MRC2 in the cornea, which are expressed by pro-angiogenic macrophages. Moreover, the number of CD11b

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
MISSION® esiRNA, targeting human TNFAIP6